SCHEMBL23575685

SCHEMBL23575685

CCOC(=O)c1cnc2cc(OC)c(Br)cc2c1NC

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.55
GAA P10253 3/20 0.55
THRB P10828 1/20 0.55
MAPK1 P28482 2/20 0.51
NPSR1 Q6W5P4 4/20 0.49
TP53 P04637 4/20 0.49
ALDH1A1 P00352 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 2/20 0.49
HPGD P15428 2/20 0.49
POLB P06746 1/20 0.49
RAB9A P51151 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
DPP4 P27487 3/20 0.49
KMT2A Q03164 1/20 0.48
KDM4E B2RXH2 3/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23575452 0.89 CSF1R (0.49) MAPTGAATHRBMAPK1
SCHEMBL23575246 0.85 MAPT (0.61) MAPTGAATHRBTP53ALDH1A1
SCHEMBL2910297 0.85 MAPT (0.59) MAPTGAATHRBTP53
SCHEMBL23575679 0.85 MAPK1 (0.52) MAPTGAATHRBMAPK1NPSR1
SCHEMBL23575162 0.84 EGFR (0.57)
SCHEMBL4081004 0.84 MAPT (0.58) MAPTGAATHRBNPSR1TP53
SCHEMBL2904279 0.84 MAPT (0.54) MAPTGAATHRBMAPK1NPSR1
SCHEMBL5929672 0.84 MAPT (0.65) MAPTGAATHRBTP53
SCHEMBL23575157 0.84 MAPT (0.71) MAPTGAATHRBMAPK1NPSR1
SCHEMBL2904593 0.84 MAPT (0.64) MAPTGAATHRBTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3846800-A1 COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 C4 Therapeutics, Inc. (US) 2021-07-14 EP disclosed
US-20210198256-A1 COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 C4 THERAPEUTICS, INC. (US) 2021-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210198256-A1 COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 RBBP9, MTHFD1, BRWD1 MAPT 843/4885GAA 1619/4885THRB 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.